Sunrest LifescienceNSE:SUNREST 41 EBITDA Margin % is 25.16% as of Mar. 2026, which is 446% above its 10-year median of 4.61. GuruFocus rates NSE:SUNREST with a GF Score™ of 41/100. The stock has 5 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Sunrest Lifescience ranks better than 84.73% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Sunrest Lifescience EBITDA Margin % Related Terms
Sunrest Lifescience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Sunrest Lifescience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Sunrest Lifescience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunrest Lifescience EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sunrest Lifescience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Sunrest Lifescience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunrest Lifescience (NSE:SUNREST) has a EBITDA Margin % of 25.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunrest Lifescience and its competitors. This is 446% above median its historical median of 4.61. Over the past decade, Sunrest Lifescience's EBITDA Margin % has ranged from 1.43 to 25.16. According to the industry distribution chart, Sunrest Lifescience ranks #102 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 15.3%.
Is Sunrest Lifescience's EBITDA Margin % too high?
Sunrest Lifescience's current EBITDA Margin % of 25.16% is 446% above median its 10-year median of 4.61. Over the past 10 years, this metric has ranged from a low of 1.43 to a high of 25.16. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Sunrest Lifescience's value of 25.16% is 146.4% above this industry median. Based on the distribution chart, Sunrest Lifescience ranks #102 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Sunrest Lifescience has a GF Score™ of 41/100, reflecting its overall financial health beyond just this single metric.
How does Sunrest Lifescience's EBITDA Margin % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Sunrest Lifescience ranks #102 out of 668 companies for EBITDA Margin %. This places Sunrest Lifescience in the top 15% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Sunrest Lifescience's value of 25.16% is 146.4% above this benchmark. Historically, Sunrest Lifescience's own EBITDA Margin % has ranged from 1.43 to 25.16 over the past decade. While the company's 10-year median is 4.61 vs. the industry median of 10.21, Sunrest Lifescience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunrest Lifescience's current EBITDA Margin % of 25.16% is 146.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Sunrest Lifescience and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunrest Lifescience's current EBITDA Margin % is 25.16%, which is 446% above median its own 10-year median of 4.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunrest Lifescience stock overvalued right now?
Sunrest Lifescience (NSE:SUNREST) has a current EBITDA Margin % of 25.16%. The current EBITDA Margin % is 25.16%, which is 446% above median its 10-year median of 4.61 and 146.4% above the Healthcare Providers & Services industry median of 10.21. Sunrest Lifescience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Sunrest Lifescience (NSE:SUNREST), the current EBITDA Margin % is 25.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunrest Lifescience Ltd is engaged in the trading business of pharmaceutical products, including capsules, tablets, syrups, ointments, gels, mouthwash, and toothpaste on a wholesale and retail basis. Its product portfolio covers categories such as anti-bacterial, anti-diarrheal, anti-fungal, anti-malarial, anti-diabetic, dental care, anti-inflammatory, nutraceuticals, and more. The company works with a network of suppliers and super suppliers, distributing products to chemists, hospitals, and dispensaries across multiple Indian states. Sunrest relies on both in-house manufacturing through its group company Trilend Pharmaceuticals and third-party manufacturers, emphasizing quality control and regulatory compliance.
41GF Score
Get the complete analysis for NSE:SUNREST
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SUNREST has been successfully added to your 
